Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Antivir Ther. 2018;23(1):1–9. doi: 10.3851/IMP3193

Table 3.

Immune, Inflammatory, Metabolic, and Coronary Plaque Parameters among Non-HIV-Infected and HIV-Infected Women Stratified by Within-Group Median Epicardial Adipose Tissue Volume

Non-HIV-Infected
Below Median EAT Volume (n=13)
HIV-Infected
Below Median EAT Volume (n=27)
Non-HIV-Infected
Above Median EAT Volume (n=14)
HIV-Infected
Above Median EAT Volume (n=28)
Overall P Value
Markers of Monocyte/Macrophage Activation*

MCP-1, pg/mL 166 ± 31 235 ± 22 249 ± 31 262 ± 22 0.10
CXCL10, pg/mL 131 ± 60 285 ± 43 179 ± 60 305 ± 42 0.02a,c,f
sCD163, ng/mL 984 ± 237 1642 ± 171 1506 ± 237 1896 ± 167 0.004a,c
sCD14, ng/mL 1594 ± 406 2021 ± 293 1310 ± 406 2488 ± 287 0.03f

Inflammatory Markers*

hsIL6, pg/mL 1.68 ± 0.32 1.56 ± 0.25 1.94 ± 0.32 2.20 ± 0.24 0.32
Lp-PLA2, nmol/min/mL 135 ± 14 174 ± 10 168 ± 14 176 ± 10 0.04a,b,c

Plaque Characteristics**

Presence of coronary plaque, % 23 40 54 33 0.41
Segments with noncalcified plaque, % 33 ± 19 [0 (0,100)] 71 ± 10 [71 (63,100)] 19 ± 13 [0 (0,44)] 78 ± 12 [88 (54,100)] 0.009 (0.047)d,f
Segments with mixed plaque, % 13 ± 16 [0 (0,40)] 27 ± 9 [25 (0,33)] 51 ± 11 [42 (31,75)] 17 ± 10 [0 (0,33)] 0.13 (0.13)
Segments with calcified plaque, % 53 ± 14 [60 (0,100)] 3 ± 8 [0 (0,0)] 40 ± 9 [33 (0,67)] 5 ± 9 [0 (0,13)] 0.003 (0.01)a,c,d,f

Metabolic Parameters

Fasting glucose, mg/dL 78 ± 10 91 ± 7 88 ± 10 90 ± 7 0.75
Triglycerides, mg/dL 85 ± 17 113 ± 12 134 ± 17 104 ± 12 0.24

Abbreviations: EAT, epicardial adipose tissue; MCP-1, monocyte chemoattractant protein-1; CXCL10, C-X-C motif chemokine 10; sCD163, soluble CD163; sCD14, soluble CD14; hsIL6, high sensitivity interleukin 6; Lp-PLA2, lipoprotein-associated phospholipase A2

*

Data reported as mean ± standard error; overall P value by ANOVA. Data for markers of monocyte/macrophage activation and generalized inflammation are presented prior to log transformation only for purposes of clinical interpretation; the appropriate statistical test was applied after log-transformation.

**

For plaque segment data, non-normally distributed data also reported as [median (IQR)]; overall P value by Kruskal-Wallis test.

a

P < 0.05 Non-HIV-Infected Below Median EAT vs. HIV-Infected Below Median EAT

b

P < 0.05 Non-HIV-Infected Below Median EAT vs. Non-HIV-Infected Above Median EAT

c

P < 0.05 Non-HIV-Infected Below Median EAT vs. HIV-Infected Above Median EAT

d

P < 0.05 HIV-Infected Below Median EAT vs. Non-HIV-Infected Above Median EAT

e

P < 0.05 HIV-Infected Below Median EAT vs. HIV-Infected Above Median EAT

f

P < 0.05 Non-HIV-Infected Above Median EAT vs. HIV-Infected Above Median EAT